Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Hiroto Matsui Matsui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3588-8751; OpenAlex author ID A5019896646, A5109650606. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 24

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy. Co-author DOI 10.1016/j.suronc.2025.102333↗
  3. Immature Peritumoral Tertiary Lymphoid Structures Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After NAC. Co-author DOI 10.21873/anticanres.18061↗
  4. Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003). Co-author DOI 10.1002/cam4.70647↗
  5. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.1111/cas.70087↗
  6. Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). Co-author DOI 10.1097/mpa.0000000000002323↗
  7. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers16142522↗
  8. [A Case of Pancreatic Cancer with Concomitant Pancreatic Metastasis of Renal Cell Carcinoma]. First author PMID 39948974↗
  9. Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study. Co-author DOI 10.21873/invivo.13380↗
  10. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000527342↗
  11. Hepatic artery resection and reconstruction using the right gastroepiploic artery during pancreaticoduodenectomy in advanced pancreatic cancer. Co-author DOI 10.1007/s00423-021-02120-0↗
  12. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Co-author DOI 10.1097/mpa.0000000000001772↗
  13. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000511940↗
  14. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Co-author DOI 10.3892/ol.2020.12291↗
  15. [Five Cases of Ten-Year Survival after Surgical Treatment of Pancreatic Cancer in Yamaguchi Prefecture]. First author PMID 32156955↗
  16. Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Co-author DOI 10.1080/14737140.2018.1531707↗
  17. Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection. Co-author DOI 10.1097/mcg.0000000000000551↗
  18. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Co-author DOI 10.1097/mpa.0000000000000880↗
  19. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  20. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  21. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Co-author DOI 10.1111/cas.13061↗
  22. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy]. Co-author PMID 28133195↗
  23. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000012↗
  24. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1186/1479-5876-12-175↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroaki Nagano · 19 shared papers, 2016–2026 · strength 2.64
  2. Yoshitaro Shindo · 21 shared papers, 2014–2026 · strength 2.62
  3. Tatsuya Ioka · 9 shared papers, 2021–2026 · strength 1.79
  4. Masao Nakajima · 9 shared papers, 2017–2026 · strength 1.64
  5. Ryouichi Tsunedomi · 7 shared papers, 2016–2026 · strength 1.21
  6. Hidenori Takahashi · 4 shared papers, 2024–2026 · strength 0.89
  7. Nobuaki Suzuki · 11 shared papers, 2014–2023 · strength 0.87
  8. Yusaku Watanabe · 4 shared papers, 2016–2026 · strength 0.68
  9. Taro Takami · 4 shared papers, 2021–2025 · strength 0.59
  10. Satoshi Matsukuma · 6 shared papers, 2016–2021 · strength 0.50
  11. Tomio Ueno · 9 shared papers, 2014–2019 · strength 0.46
  12. Kimikazu Hamano · 3 shared papers, 2019–2025 · strength 0.45
  13. Hidekazu Tanaka · 2 shared papers, 2024–2025 · strength 0.37
  14. Hiroaki Nagano · 3 shared papers, 2017–2024 · strength 0.35
  15. Isao Sakaida · 3 shared papers, 2019–2022 · strength 0.31
  16. Yasuhiro Fujiwara · 3 shared papers, 2019–2021 · strength 0.30
  17. Masaaki Oka · 6 shared papers, 2014–2017 · strength 0.27
  18. Yutaka Suehiro · 3 shared papers, 2014–2022 · strength 0.26
  19. Takahiro Yamasaki · 3 shared papers, 2014–2022 · strength 0.26
  20. Mari Nabeya · 1 shared paper, 2026 · strength 0.26
  21. Katsuyoshi Ito · 2 shared papers, 2019–2024 · strength 0.25
  22. Hirofumi Akita · 1 shared paper, 2025 · strength 0.25
  23. Gen Kanesada · 1 shared paper, 2025 · strength 0.25
  24. Yuko Fujimoto · 2 shared papers, 2021–2022 · strength 0.23
  25. Shigeyuki Suenaga · 2 shared papers, 2021–2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.